Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions
Physiologic changes due to disease status can lead to highly variable pharmacokinetics (PK) of amikacin in children. Therefore, considerations should be given when determining optimal amikacin does for patients with a specific diseases. Improved understanding of factors influencing PD can allow for the optimizing of dosage regimens to reduce adverse effects.
The aim of the study was to undertake a comparative pharmacometic analysis of amikacin use in pediatric patients with burn injuries verses those with oncology conditions.
Kagan, R. J.,
Healy, D. P.,
& Sherwin, C. M.
(2016). Amikacin Pharmacokinetics in Pediatric Patients with Burn Injuries Compared to Those with Oncology Conditions. .
World Conference of Pharmacometrics (WCoP), Brisbane, Australia.